Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations
Open accessThe DOI matches its Crossref record; 271 of the 271 references it cites were found in a registry or an index.
Abstract
Administration of the chemotherapeutic agent cisplatin leads to acute kidney injury (AKI). Cisplatin-induced AKI (CIAKI) has a complex pathophysiological map, which has been linked to cellular uptake and efflux, apoptosis, vascular injury, oxidative and endoplasmic reticulum stress, and inflammation. Despite research efforts, pharmaceutical interventions, and clinical trials spanning over several decades, a consistent and stable pharmacological treatment option to reduce AKI in patients receiving cisplatin remains unavailable. This has been predominately linked to the incomplete understanding of CIAKI pathophysiology and molecular mechanisms involved. Herein, we detail the extensively known pathophysiology of cisplatin-induced nephrotoxicity that manifests and the variety of pharmacological and genetic alteration studies that target them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–271 of 271
Busconi, L., Bauer, J. W., Tumang, J. R., Laws, A., Perkins-Mesires, K., Tabor, A. S., Lau, C., Corley, R. B., Rothstein, T. L., Lund, F. E., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7397 · Cited by 59
Zhang, J., Rudemiller, N. P., Patel, M. B., Wei, Q., Karlovich, N. S., Jeffs, A. D., Wu, M., Sparks, M. A., Privratsky, J. R., Herrera, M., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015060683 · Cited by 58
Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences
Nematbakhsh, M., Pezeshki, Z., Eshraghi-Jazi, F., Mazaheri, B., Moeini, M., Safari, T., Azarkish, F., Moslemi, F., Maleki, M., Rezaei, A., et al. (2017) · PubMed Central · doi:10.22034/apjcp.2017.18.2.295 · Cited by 57
TAK1 mediates excessive autophagy via p38 and ERK in cisplatin‐induced acute kidney injury
Zhou, J., Fan, Y., Zhong, J., Huang, Z., Huang, T., Lin, S., & Chen, H. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13585 · Cited by 56
Ning, Y., Shi, Y., Chen, J., Song, N., Cai, J., Fang, Y., Yu, X., Ji, J., & Ding, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00384 · Cited by 56
Nieskens, T. T. G., Peters, J. G. P., Dabaghie, D., Korte, D., Jansen, K., van Asbeck, A. H., Tavraz, N. N., Friedrich, T., Rüssel, F. G. M., Masereeuw, R., et al. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079384 · Cited by 55
Discovery of novel small molecule TLR4 inhibitors as potent anti-inflammatory agents
Xu, Y., Chen, S., Cao, Y., Zhou, P., Chen, Z., & Cheng, K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.05.033 · Cited by 55
Huang, Z., Guo, F., Xia, Z., Liang, Y., Song, L., Tan, Z., Ma, L., & Fu, P. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110056 · Cited by 55
Hao, Q., Xiao, X., Zhen, J., Feng, J., Song, C. X., Jiang, B., & Hu, Z. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5714 · Cited by 54
Yang, Y., Liu, S., Gao, H., Wang, P., Zhang, Y., Zhang, A., Jia, Z., & Huang, S. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.01.182 · Cited by 54
Renal effects of treatment with a TLR4 inhibitor in conscious septic sheep
Fenhammar, J., Rundgren, M., Hultenby, K. R., Forestier, J., Taavo, M., Kenne, E. M., Weitzberg, E., Eriksson, S., Özenci, V., Wernerson, A. M., et al. (2014) · Critical Care · doi:10.1186/preaccept-1770070480124389 · Cited by 53
Measurement of malondialdehyde as oxidative stress biomarker in goat plasma by HPLC-DAD
Yonny, M. E., García, E. M., López, A., et al. (2016) · Microchemical Journal · doi:10.1016/j.microc.2016.07.010 · Cited by 53
Volarević, V., Marković, B. S., Gazdic, M., Djokovic, B., Jovicic, N. U., Harrell, C. R., Fellabaum, C., Djonov, V., Arsenijević, N., & Lukić, M. L. (2019) · Theranostics · doi:10.7150/thno.33959 · Cited by 53
Chen, B., Liu, G., Zou, P., Li, X., Hao, Q., Jiang, B., Yang, X., & Hu, Z. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215573394 · Cited by 52
Hoffmann, E. K., Sørensen, B. H., Sauter, D. P. R., & Lambert, I. H. (2015) · Channels · doi:10.1080/19336950.2015.1089007 · Cited by 52
Targeting Oct2 and P53: Formononetin prevents cisplatin-induced acute kidney injury
Huang, D., Wang, C., Duan, Y., Meng, Q., Liu, Z., Huo, X., Sun, H., Ma, X., & Liu, K. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.04.013 · Cited by 52
Wolf, S. C., Sauter, G., Preyer, M., Poerner, T. C., Kempf, V. A. J., Risler, T., & Brehm, B. R. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000099201 · Cited by 50
Skin Redox Balance Maintenance: The Need for an Nrf2-Activator Delivery System
Ben-Yehuda Greenwald, M., Ben-Sasson, S., Bianco-Peled, H., & Kohen, R. (2016) · Cosmetics · doi:10.3390/cosmetics3010001 · Cited by 49 · cited 1×
“Nrf2 is responsible for maintenance of the cellular redox balance, antioxidant response, and phase II detoxification process [104].”
BackgroundNebivolol Ameliorates Cisplatin‐Induced Nephrotoxicity in Rats
Morsy, M. A., & Heeba, G. H. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12538 · Cited by 49
Interleukin-6 deficiency accelerates cisplatin-induced acute renal failure but not systemic injury
Mitazaki, S., Kato, N., Suto, M., Hiraiwa, K., & Abe, S. (2009) · Toxicology · doi:10.1016/j.tox.2009.10.005 · Cited by 48
El‐kader, M. A., & Taha, R. I. (2020) · Acta Histochemica · doi:10.1016/j.acthis.2020.151534 · Cited by 48
CXCL16 Deficiency Attenuates Renal Injury and Fibrosis in Salt-Sensitive Hypertension
Liang, H., Ma, Z., Peng, H., Li-qun, H., Hu, Z., & Wang, Y. (2016) · Scientific Reports · doi:10.1038/srep28715 · Cited by 47
Kidney Proximal Tubular TLR9 Exacerbates Ischemic Acute Kidney Injury
Han, S. J., Li, H., Kim, M., Shlomchik, M. J., & Lee, H. T. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800211 · Cited by 47
Shamsul, H. M., Hasebe, A., Iyori, M., Ohtani, M., Kiura, K., Zhang, D., Totsuka, Y., & Shibata, K. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03232.x · Cited by 45
Jessé, C. R., Bortolatto, C. F., Wilhelm, E. A., et al. (2012) · Journal of Applied Toxicology · doi:10.1002/jat.2818 · Cited by 45
Kurup, S. P., & Tarleton, R. L. (2013) · Nature Communications · doi:10.1038/ncomms3616 · Cited by 45
Angiotensin converting enzyme 2 and diminazene
Velkoska, E., Patel, S. K., & Burrell, L. M. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000254 · Cited by 45
Xu, L., Xie, Q., Qi, L., Wang, C., Xu, N., Liu, W., Yu, Y., Li, S., & Xu, Y. (2017) · Oncology Reports · doi:10.3892/or.2017.6164 · Cited by 45
Fox, E., Levin, K., Zhu, Y., Segers, B., Balamuth, N., Womer, R. B., Bagatell, R., & Balis, F. M. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0037 · Cited by 44
Raby, A., Gónzalez-Mateo, G. T., Williams, A., Topley, N., Fraser, D. J., López‐Cabrera, M., & Labéta, M. O. (2018) · Kidney International · doi:10.1016/j.kint.2018.03.014 · Cited by 44
Tan, Z., Guo, F., Huang, Z., Xia, Z., Liu, J., Tao, S., Li, L., Feng, Y., Du, X., Ma, L., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14512 · Cited by 44
The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?
Ruggiero, A., Rizzo, D., Trombatore, G., Maurizi, P., & Riccardi, R. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2913-6 · Cited by 43
Ullah, M., Liu, D. D., Rai, S., Concepcion, W., & Thakor, A. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114085 · Cited by 43
Mitazaki, S., Honma, S., Suto, M., Kato, N., Hiraiwa, K., Yoshida, M., & Abe, S. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.04.016 · Cited by 42
Suchi, K., Fujiwara, H., Okamura, S., Okamura, H., Umehara, S., Todo, M., Furutani, A., 米田, 政., Shiozaki, A., Kubota, T., et al. (2011) · PubMed · Cited by 42
Rashidi, N., Mirahmadian, M., Jeddi‐Tehrani, M., Rezania, S., Ghasemi, J., Kazemnejad, S., Mirzadegan, E., Vafaei, S., Kashanian, M., Rasoulzadeh, Z., et al. (2015) · PubMed Central · Cited by 42
Saito, K., Kukita, K., Kutomi, G., Okuya, K., Asanuma, H., Tabeya, T., Naishiro, Y., Yamamoto, M., Takahashi, H., Torigoe, T., et al. (2015) · European Journal of Immunology · doi:10.1002/eji.201445293 · Cited by 41
The protective effects of Zhen-Wu-Tang against cisplatin-induced acute kidney injury in rats
Liu, Q., Shou-yu, H., He, Y., Zhang, J., Zeng, X., Gong, F., & Liang, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179137 · Cited by 41
Varagić, J., Ahmad, S., VonCannon, J. L., Moniwa, N., Simington, S., Brosnihan, B., Gallagher, P. E., Habibi, J., Sowers, J. R., & Ferrario, C. M. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e328356766f · Cited by 39
Hyperhomocysteinemia Exacerbates Cisplatin-induced Acute Kidney Injury
Long, Y., Zhen, X., Zhu, F., Hu, Z., Lei, W., Li, S., Zha, Y., & Nie, J. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.16725 · Cited by 39
Potočnjak, I., Marinić, J., Batičić, L., Šimić, L., Broznić, D., & Domitrović, R. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111472 · Cited by 37
Chen, M.-F., Yang, C., Su, C.-M., & Hu, M. (2014) · Nutrition and Cancer · doi:10.1080/01635581.2014.948211 · Cited by 36
CXCL16 regulates cisplatin-induced acute kidney injury
Liang, H., Zhang, Z., Li-qun, H., & Wang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9386 · Cited by 36
Oh, S.-M., Park, G., Lee, S., Seo, C., Shin, H., & Oh, D. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-2055-y · Cited by 35
Kashani, B., Zandi, Z., Karimzadeh, M. R., Bashash, D., Nasrollahzadeh, A., & Ghaffari, S. H. (2019) · Immunologic Research · doi:10.1007/s12026-019-09113-8 · Cited by 35
Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow?
Bennis, Y., Savry, A., Rocca, M., Gauthier-Villano, L., Pisano, P. S., & Pourroy, B. (2014) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9912-7 · Cited by 34
Endogenous Toll-Like Receptor 9 Regulates AKI by Promoting Regulatory T Cell Recruitment
Alikhan, M. A., Summers, S. A., Gan, P., Chan, A. J., Khouri, M. B., Ooi, J. D., Ghali, J. R., Odobasic, D., Hickey, M. J., Kitching, A. R., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014090927 · Cited by 32
Okui, S., Yamamoto, H., Li, W., Gamachi, N., Fujita, Y., Kashiwamura, S., Miura, D., Takai, S., Miyazaki, M., Urade, M., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.04.027 · Cited by 28
Effect of levosimendan, a calcium sensitizer, on cisplatin-induced nephrotoxicity in rats
Abdelrahman, A. M., Suleimani, Y. M. A., Shalaby, A., Ashique, M., Manoj, P., Al-Saadi, H., & Ali, B. H. (2019) · Toxicology Reports · doi:10.1016/j.toxrep.2019.02.006 · Cited by 28
Self-citationSherif, I. O., Al-Mutabagani, L. A., Alnakhli, A. M., Sobh, M. A. K., & Mohammed, H. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215577582 · Cited by 27
The Role of Toll-Like Receptor 4 in Cisplatin-Induced Renal Injury
Cenedeze, M. A., Gonçalves, G. M., Feitoza, C. Q., Wang, P. M. H., Damião, M. J., Bertocchi, A. P. F., Pacheco‐Silva, Á., & Câmara, N. O. S. (2007) · Transplantation Proceedings · doi:10.1016/j.transproceed.2007.01.032 · Cited by 26
Shen, Q., Zhang, X., Li, Q., Zhang, J., Lai, H., Gan, H., Du, X., & Li, M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27722 · Cited by 26
Brooks, J. C., Sun, W., Chiosis, G., & Leifer, C. A. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.04.083 · Cited by 24
Yang, W. S., Kim, J., Han, N. J., Lee, M. J., & Park, S.-K. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000374034 · Cited by 24
Baek, S. H., Kim, S. H., Kim, J. W., Kim, Y. J., Lee, K., & Na, K. R. (2015) · Trials · doi:10.1186/s13063-015-0772-4 · Cited by 21
Dimethyl fumarate ameliorates cisplatin-induced renal tubulointerstitial lesions
Sasaki, A., Koike, N., Murakami, T., & Suzuki, K. (2019) · Journal of Toxicologic Pathology · doi:10.1293/tox.2018-0049 · Cited by 21
Adenosine kinase inhibition protects against cisplatin-induced nephrotoxicity
Cao, W., Yuan, Y., Liu, X., Li, Q., An, X., Huang, Z., Wu, L., Zhang, B., Zhang, A., & Xing, C. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00385.2018 · Cited by 21
Yan, H., Guo, F., Huang, Z., Feng, Y., Xia, Z., Liu, J., Li, L., Huang, R., Lin, L., Ma, L., et al. (2020) · Bioscience Reports · doi:10.1042/bsr20191538 · Cited by 19
Jiang, S., & Chen, X. (2017) · Medical Science Monitor · doi:10.12659/msm.902193 · Cited by 18
Loss of DEPTOR in renal tubules protects against cisplatin-induced acute kidney injury
Wang, C., Dai, H., Xiong, Z. Q., Song, Q., Zou, Z., Li, M., Nie, J., Bai, X., & Chen, Z. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0483-3 · Cited by 18
Ciferská, H., Hořák, P., Konttinen, Y., Krejčí, K., Tichý, T., Heřmanová, Z., & Zadražil, J. (2008) · Lupus · doi:10.1177/0961203307088130 · Cited by 16
Ravichandran, K., Holditch, S. J., Brown, C. N., Wang, Q., Özkök, A., Weiser‐Evans, M. C. M., Nemenoff, R. A., Miyazaki, M., Thiessen‐Philbrook, H., Parikh, C. R., et al. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00040.2017 · Cited by 15
Loss of α(E)-catenin promotes Fas mediated apoptosis in tubular epithelial cells
Wang, X., & Parrish, A. R. (2015) · APOPTOSIS · doi:10.1007/s10495-015-1129-x · Cited by 14
Dessing, M. C., Kers, J., Damman, J. J., Leuvenink, H. G. D., van Goor, H., Hillebrands, J., Hepkema, B. G., Snieder, H., van den Born, J., de Borst, M. H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139769 · Cited by 13
Mizuno, T., Sato, W., Ishikawa, K., Terao, Y., Takahashi, K., Noda, Y., Yuzawa, Y., & Nagamatsu, T. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s86743 · Cited by 10
The Roles of CXCL16 and CXCR6 in Liver Inflammation and Fibrosis
Wehr, A., & Tacke, F. (2015) · Current Pathobiology Reports · doi:10.1007/s40139-015-0090-2 · Cited by 8
INNATE IMMUNITY IN NEPHROTOXIC ACUTE KIDNEY INJURY.
Reeves, W. B. (2019) · PubMed · Cited by 8
Hanif, M. O., Bali, A., & Ramphul, K. (2019) · StatPearls · Cited by 7
Lalan, M. S., Bagchi, T., & Misra, A. R. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-384964-9.00001-3 · Cited by 7
Imipridone enhances vascular relaxation via FOXO1 pathway
McSweeney, K. R., Gadanec, L. K., Qaradakhi, T., Gammune, T. M., Kubatka, P., Čaprnda, M., Fedotova, J., Radoňak, J., Kružliak, P., & Zulli, A. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13377 · Cited by 4
Self-citationKadir, A., Ibrahim, S., Shah, S. N. N., Aslam, Z., Siddiqui, R. A., Baig, M. T., Shah, M. R., Mirza, T., Sımjee, S. U., & Arsalan, A. (2020) · PubMed · Cited by 4
Cited by
Pyroptosis in health and disease: mechanisms, regulation and clinical perspective
Liu, Y., Pan, R., Ouyang, Y., Gu, W., Xiao, T., Yang, H., Tang, L., Wang, H., Xiang, B., & Chen, P. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01958-2 · Cited by 337
Metadata
- Authors
- McSweeney, K. R., Gadanec, L. K., Qaradakhi, T., Ali, B. A., Zulli, A., & Apostolopoulos, V.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-03-29
- Volume
- 13
- Issue
- 7
- Pages
- 1572
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3150252631
- Cited by
- 363
- References
- 271
- FWCI
- 32.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.